HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125
Monopar Therapeutics Inc MNPR
$108.35
▼ -5.50%
($-6.31)
🔥 High Short Interest
🎈 Low Float
🗓️ Earnings Next Week
Open
$114.80
Prev Close
$114.66
Day Range
$107.11 – $116.69
52W Range
$29.18 – $116.69
Market Cap
$725.84M
Beta
1.46
EPS (TTM)
$-1.90
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-12-19 |
| Shares Out. | 6,700,000 |
| Website | monopartx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 22 |
| Net Income | -$3.9M |
| Total Assets | $138.0M |
| Total Liabilities | $2.6M |
| Equity | $135.4M |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Monopar Therapeutics Inc is a publicly traded company under the ticker symbol MNPR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)